Search clinical trials for: SCD-101

Total 8031 results

CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
CuraSen Therapeutics, Inc.

Not yet recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Freezing of Gait Symptoms in Parkinson's Disease

Australia
National Cancer Institute (NCI)

Terminated

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
Ornovi, Inc.

Withdrawn

A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects

Alopecia Areata

Australia
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
Fondation Ophtalmologique Adolphe de Rothschild

Completed

Implications of a Paediatrician-psychologist Tandem for Sickle Cell Disease Care and Impact on Cognitive Functioning

Sickle Cell Disease
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
MJM Bonten
Paris 12 Val de Marne University

Completed

Ecological Effects of Decolonisation Strategies in Intensive Care (RGNOSIS)

ICU-ecology (Multidrug Resistant Bacteria) | ICU-acquired Bacteraemia

Belgium, Spain, United Kingdom, Italy, Portugal, Slovenia
University of Michigan
Renal Research Institute

Terminated

Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients (ESRD)

End Stage Renal Disease | Acute Kidney Injury | Chronic Kidney Disease Stage 5

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)

Myotonic Dystrophy Type 1 (DM1)

United Kingdom, France, Netherlands, Italy, Germany, New Zealand
Kanyos Bio, Inc., a wholly-owned subsidiary of...

Completed

Assessment of KAN-101 in Celiac Disease (ACeD)

Celiac Disease

United States
Xeno Biosciences

Completed

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

Healthy

Hungary
Bright Minds Biosciences Pty Ltd

Completed

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Healthy

Australia
Novartis Gene Therapies

Completed

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy 1

United States
Teres Bio, Inc.

Completed

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Acute Tinnitus 2 (TACTT2)

Tinnitus

United States
Arava Bio Tech Ltd.
Cato Research

Unknown

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Wounds and Injuries

United States
Vicept Therapeutics, Inc.
Accenture

Completed

Dose Response Study of Patients With Erythematous Rosacea

Erythematous (Type One) Rosacea

United States
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada
Acanthas Pharma Inc

Withdrawn

A Study of Single Ascending Doses of STAR-101 in Healthy Participants

Healthy Volunteers
Alpine Immune Sciences, Inc.
Clinical Network Services (CNS) Pty Ltd

Completed

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Healthy Volunteers

Australia
Arava Bio Tech Ltd.

Unknown

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Wounds | Other Ulcers Wounds and Skin Problems

Israel
Janssen Research & Development, LLC
Hoffmann-La Roche

Terminated

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Depression

United States
Minerva Neurosciences

Completed

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Schizophrenia

United Kingdom
Alaunos Therapeutics

Unknown

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Multiple Myeloma

United States
Alaunos Therapeutics

Unknown

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

HEPATOCELLULAR CARCINOMA

United States
Medical University of South Carolina

Completed

A Self-Management Intervention for Youth With Sickle Cell Disease and Their Families: Phase I

Anemia, Sickle Cell

United States
Mozart Therapeutics Australia Pty Ltd

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Type 1 Diabetes | Celiac Disease | Healthy Volunteers

Australia
CorrectSequence Therapeutics Co., Ltd

Recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd

Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Beta-Thalassemia

China
Tvardi Therapeutics, Incorporated

Recruiting

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Transposon Therapeutics, Inc.

Recruiting

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Aicardi-Goutières Syndrome (AGS)

United Kingdom, France, Italy
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Corat Therapeutics Gmbh

Recruiting

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Covid19

Germany
Canadian Cancer Trials Group
Canadian Cancer Society (CCS); ATGen Canada Inc; Ontario Institute for Cancer... and other collaborators

Active, not recruiting

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)

Covid-19 | Cancer

Canada
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
1ST Biotherapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany

Search clinical trials for: SCD-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations